Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2 (COVID-19)

The investigational vaccine candidates (BNT162b1 and BNT162b2) are currently undergoing Phase 1/2 clinical studies in the US and Germany. Subject to regulatory approval, a Phase 2b/3 trial enrolling up to 30,000 subjects is expected later this month.


Biospace Inc.